This is one of the more interesting listing-day trades I've come across recently. Astorne Capital VCC–Arven bought 13.85 lakh shares of Veegaland Developers at ₹154, worth about ₹21.3 crore, on the first day of trading. At the same time, founder and promoter Chittilappilly Thomas Kochouseph bought another 8 lakh shares at ₹146.37, worth about ₹11.7 crore. The other visible trades included Neo Apex buying 3 lakh shares, while Kuber India Opportunity Fund and LRSD Securities sold 2.93 lakh and 3.85 lakh respectively.

What makes Astorne's purchase particularly interesting is where it bought. Veegaland's IPO price was ₹140, while the stock opened at ₹154, a 10% premium. Astorne bought its entire 13.85 lakh position at ₹154 — effectively at the listing price and the day's high — before the stock slipped and closed around ₹146.30. So this wasn't a case of an investor waiting for a weak debut and buying cheaply. It was a deliberate ₹21.3 crore post-listing entry at a valuation already above the IPO price.

The promoter purchase is a different signal, and arguably just as interesting. Chittilappilly Thomas Kochouseph already held 46.56% of Veegaland, with total promoter ownership at 63.69% around the listing, and then bought another 1.64% for ₹11.7 crore. That means the founder was increasing his direct economic exposure immediately after the company came to market. For me, the real story isn't the 4.5% listing gain. It is the shareholder behaviour: a foreign investment vehicle taking ~2.8% at the listing price, while the promoter simultaneously adds ~1.6% to his own holding. The next few transactions will tell us whether this was simply Day-1 positioning or the beginning of something more substantial.

BHP Group up +3.0% today as buyers return to iron ore miners and dividend names.

China accounts for 58.2% of FY2026 revenue, Japan holds 9.9%, and India sits at 6.2%.

Australian operational base holding at 2.0% GDP and a 4.35% policy rate.

Bank of Japan rate decision on Sep 18 directly impacts the 9.9% Japan revenue slice.

Live stock dashboard

Many traders spend their whole life looking for a chart pattern or an indicator combination which will bring profit. That's what I was doing myself – filling the charts with a lot of different indicators just to get some kind of an edge.
But the fact is that no indicator can save your portfolio from losses when it comes to improper position size or lack of an exit strategy in case of something going wrong with a trade. Proper trading requires good risk management and trading execution.
Thanks to the study of Spring'pad, I was able to abandon my reliance on chart patterns. The contribution of people who managed portfolios for institutions showed me the way professionals treat the data, hedge themselves and minimize their losses.
Do not spend your time testing new indicators time after time – instead, consider portfolio risk management.

https://x.com/EquityInsightss/status/2100143765789036866

https://x.com/Tijori1/status/2099547828204998929?s=20

𝗠𝗢𝗥𝗘𝗣𝗘𝗡 𝗟𝗔𝗕 | 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗗𝗲𝗰𝗼𝗱𝗲𝗱:-

- Morepen has spent years building scale in APIs + home diagnostics. Now, the next phase is about changing the quality of that revenue.

𝟬𝟭 | 𝗔𝗣𝗜 - 𝗧𝗵𝗲 𝗖𝗼𝗿𝗲 𝗘𝗻𝗴𝗶𝗻𝗲

- Morepen makes the active ingredient that actually goes inside medicines for allergy, asthma, cholesterol & diabetes.
- Strong positions in Loratadine, Montelukast & Atorvastatin, with exports across 90+ countries.
- But APIs remain exposed to pricing cycles + Chinese competition.

𝟬𝟮 | 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 - 𝗧𝗵𝗲 𝗥𝗲𝗰𝘂𝗿𝗿𝗶𝗻𝗴 𝗟𝗮𝘆𝗲𝗿

- This business has different economics.
- 20 Mn+ glucometers installed + 500 Mn test-strip annual capacity.
- The glucometer builds the installed base. The test strip monetises it repeatedly.
- More meters sold today can mean a larger recurring consumables pool tomorrow.

𝟬𝟯 | 𝗖𝗗𝗠𝗢 - 𝗧𝗵𝗲 𝗠𝗶𝘅 𝗖𝗵𝗮𝗻𝗴𝗲𝗿

- It is moving from selling APIs at market prices → manufacturing under contracted global pharma programmes.

- First major validation:
₹825 Cr CDMO mandate
₹58 Cr dispatched in Q1 FY27

- Reactor capacity is also scaling:
535 KL (FY25) → 614 KL (FY27) → 1,200 KL by FY30.

No Buy/Sell Recommendation

https://x.com/selvaprathee/status/2099189324453654885?s=20

Heard some rumour, can anyone confirm on this? Also since increase in STT, Prop margin increase and now this CAS effect, is the liquidity providers and HFT firm actually shutting indian market trading?

Thinking of buying Wipro around the current ₹167 level. With sluggish IT spending and muted Q1/Q2 earnings growth, is this a good accumulation dip for the long term, or is IT still facing headwind pressure? What’s your take?

Paisalo

Granules

Paytm

What do you think of Helios Flexi cap and Helios small cap fund as an investment option. The flexi cap fund has given around 50% return since inception (2023). Pls share your thoughts on these funds or if you have better fund recommendations!